Shares of Definium Therapeutics surged 19.3% in pre-market trading to $46.41 after the company reported that its experimental anxiety pill cleared the final hurdle of a second large clinical trial, putting the drug on a path toward a federal regulatory filing next year. The results matter because they could make this the first psychedelic-based medicine approved for everyday anxiety — a market estimated at $8.2 billion in 2026.

  • The Drug Worked — Again, and Across Two Separate Trials. The study met its primary and all key secondary endpoints, with patients on the higher dose achieving a 5.1-point placebo-adjusted reduction in a standard anxiety scale at 12 weeks (p<0.0001). That follows a 5.4-point advantage in the earlier Voyage trial (p<0.0001), which showed a large effect size.

This is the company's third positive late-stage readout, following a depression trial in June and the first anxiety trial in August. Three clean wins in a row significantly raise the odds the FDA will approve it.

  • An FDA Meeting Is Already Booked. Definium has scheduled a pre-application meeting with regulators in the fourth quarter of 2026 and expects to file its formal approval application in the first half of 2027. That timeline matters because every month of delay costs potential revenue in a crowded anxiety market still dominated by decades-old generic antidepressants. The FDA previously granted the drug its coveted Breakthrough Therapy designation for anxiety , which typically speeds the review process.

  • The Company Has Cash to Get There. Definium raised roughly $805 million in a June stock offering and ended Q2 with about $1.1 billion in cash and investments — enough to fund operations into 2030. That removes the risk of a dilutive emergency fundraise before a potential launch.

  • The Valuation Question Gets Harder From Here. The stock's prior market capitalization sat near $5.2 billion ; today's jump pushes that above $6 billion — for a company with zero product revenue. Analysts' average fair-value estimate recently rose to $67.47 , implying roughly 45% further upside, but that assumes smooth approval and strong commercial uptake. The broader anxiety treatment market is projected to reach $9.7 billion by 2030 , yet capturing meaningful share against cheap generics and entrenched prescribing habits remains the biggest unknown.